Despite passing the effectiveness test with an outstanding score of 90.4 percent, Novavax’s unclear route to approval in the United States may see India emerging as a significant destination for the injections, with the Serum Institute of India as a manufacturing partner.
The initial supply of Novavax’s Covid-19 vaccine would be prioritized for developing countries, according to the company’s Chief Executive Officer on Monday.
In late-stage testing, the Maryland-based business said the vaccine provided 100 percent protection against mild and severe sickness caused by SARS-CoV-2, boosting the hopes of its Indian counterpart, Covovax. The vaccination’s overall effectiveness was 90.4 percent, which means it was able to reduce symptomatic Covid-19 cases by more than 90% when compared to individuals who had not received the vaccination.
Several high-income nations have previously vaccinated huge segments of their populations with vaccines produced by other businesses, despite severe vaccine shortages in low- and middle-income nations.
Novavax, a tiny firm that benefited greatly from Trump’s Operation Warp Speed last year, also intends to complete its advance purchase agreements (APAs) with “four or five” high-income nations.
In effectiveness tests done in the United States and Mexico, Novavax received a 90.4 percent rating. Novavax, also known as Covovax in India, is in the midst of phase 2/3 bridging studies, with SII recruiting 1,600 people in 15 locations.
